We empower people with innovative treatment solutions

 

 

 

A commercial stage pharmaceutical company with three revenue generating pharmaceutical products

 

 

Development pipeline targeting large medical needs

 

 

AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products

Key News

FEBRUARY 12, 2024
Orexo and Sobi agree to advance feasability study with AmorphOX

FEBRUARY 8, 2024
Interim Report Q4 2023 incl. Full Year Report

FEBRUARY 6, 2024
OX640 study result to be presented at the 2024 AAAAI Annual Meeting in DC, Feb. 23-26, by Dr. Anne K Ellis 

To read all NEWS go to Media in the top menu 

Key financial figures

Group net revenue

639 MSEK
Last Twelve Months, Q123-Q423

Group EBITDA

-33 MSEK
Last Twelve Months, Q123-Q423

US Pharma segment EBIT

283 MSEK
Last Twelve Months, Q123-Q423

Cash position

171 MSEK
Q423

News Flow

Regulatory Press Releases

To read all NEWS go to Media in the top menu